CEACAM5 and colorectal carcinoma: Based on the above discussions, overall, one question is raised: can the use of any combination of these cellular or molecular biomarkers (i.e., the CD45neg EpCAMpos CTC count, CD45neg EpCAMneg cell count, or CEA level) improve the predictive performance for CRC disease (e.g., earlier diagnosis) or its status (e.g., advanced or metastatic CRC)?